Plus Therapeutics, Inc. (PSTV) Reports In-Line Q1 EPS

Plus Therapeutics, Inc. (NASDAQ: PSTV) reported Q1 EPS of ($0.14), in-line with the analyst estimate of ($0.14). Revenue for the quarter came in at $506 thousand versus the consensus estimate of $600 thousand.

For earnings history and earnings-related data on Plus Therapeutics, Inc. (PSTV) click here.

You May Also Be Interested In

• TPU-As-A-Service could boost Google’s 2028 profit by over 15%: Barclays
• American Express (AXP) Tops Q2 EPS by 13c
• Charter Communications (CHTR) Tops Q2 EPS by 66c